MARLBOROUGH, Mass.,
Nov. 13, 2017 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a
clinical-stage company developing a new class of RNAi-based
therapeutics, and Gustave Roussy, a
leading Comprehensive Cancer Centre in Europe, today announced that they have entered
into a collaborative research agreement to evaluate the potential
of RXi's novel sd-rxRNA technology platform for use in cancer
treatments. The agreement covers research to design and
evaluate sd-rxRNA compounds in a human tumor xenograft model.
Positive results may lead to further development of these compounds
for treatment of cancer.
Logo -
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
"We are excited to be working with Gustave Roussy on this research effort," said
Dr. Geert Cauwenbergh, President and
CEO of RXi Pharmaceuticals. He further added, "We believe
that our sd-rxRNA technology platform is broadly applicable to many
therapeutic areas, including cancer. Considering our sd-rxRNA
development for immuno-oncology applications, we look forward to
working with the exceptional team at this prominent cancer center
to leverage their expertise in this area."
Professor Caroline Robert, MD,
PhD, head of the Dermatology Unit at the Gustave Roussy Institute
which focuses on skin cancer research, said that "the innovative
technology developed by RXi will allow us to address several
critical questions in the field of cancer research and to explore
future potential use of siRNAs in the clinic."
About Gustave Roussy
Gustave Roussy, the largest
comprehensive cancer center in Europe, is a pole of expertise dedicated to
the comprehensive care of patients, employing 3,100 health
professionals for health care, research and teaching. –
www.gustaveroussy.fr/en
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that have the ability to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-and-gustave-roussy-announce-research-collaboration-300554394.html
SOURCE RXi Pharmaceuticals Corporation